Weight-loss drug semaglutide can cut hospital time as well as kilos for heart patients

Embargoed until: Publicly released: 2025-12-24 03:00

Australia; VIC

Photo by Haberdoedas on Unsplash. Story by Lyndal Byford, Australian Science Media Centre

Treatment with semaglutide can reduce the time spent in hospital for patients with cardiovascular disease who are overweight or obese, according to Australian led research. The analysis of previous clinical trial data found that for patients with cardiovascular disease who were overweight or obese, those taking semaglutide had fewer hospital admissions and spent less time in hospital.

News release

From: JAMA

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease

JAMA Cardiology
Original Investigation

About The Study: In this prespecified exploratory analysis of the SELECT randomized clinical trial, the trial cohort had a high rate of hospital admissions. Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, extending its benefits beyond cardiovascular risk reduction.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: JAMA Cardiology

Research:Paper

Organisation/s: Monash University

Funder: This trial was funded by Novo Nordisk A/S. This support was funded by Novo Nordisk in accordance with Good Publication Practice guidelines (www.ismpp.org/gpp-2022).

Media Contact/s

Contact details are only visible to registered journalists.